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Systematic deciphering of cancer Genome
networks
Bernard Fendler and Gurinder Atwal
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
When growth regulatory genes are damaged in a cell, it may become cancerous. Current
technological advances in the last decade have allowed the characterization of the whole
genome of these cells by directly or indirectly measuring DNA changes. Complementary
analyses were developed to make sense of the massive amounts of data generated. A large
majority of these analyses were developed to construct interaction networks between genes
from, primarily, expression array data. We review the current technologies and analyses
that have developed in the last decade. We further argue that as cancer genomics evolves
from single gene validations to gene network inferences, new analyses must be developed
for the different technological platforms.
introduction
Cancer is uncontrolled accelerated cel-
lular growth and is responsible for approx-
imately 13 percent of deaths worldwide [1].
Over the last half century, our understand-
ing of cancer development has evolved
from environmental to genetic causes [2,3].
While it is likely a combination of the two
[4,5], much research in the last three
decades have focused on genetic predispo-
sitions with the prevailing common dis-
ease/common variant hypothesis [6,7].
Namely, the disease (cancer) is driven by a
common set of alleles, possibly spanning
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While predisposition from certain alleles
confer susceptibility to cancer [8], random
somatic mutations throughout the lifetime of
the organism without predisposition may
also lead to similar results. In either case, ge-
nomic instability, a signature feature of can-
cer [6], leads to somatic mutations including
single nucleotide polymorphisms (SNPs†),
insertions and deletions of large or small
segments of DNA, chromosomal transloca-
tions, inversions, and other structural re-
arrangements due to broken and rejoined
DNA, epigenetic modifications (usually
chromatin modifications), and DNA acqui-
sition from other sources such as infections
from HPV [9], which all may lead to aber-
rant expression profiles or altered protein
function due to amino acid substitution.
Most acquired mutations throughout the
lifetime of an individual are likely benign;
however, when a mutation alters a gene or
the expression of a gene that confers growth,
malignant neoplasms arise. The cells within
the growing tumor are progeny of the origi-
nal cell, whose driver or set of driver genes
initiated expansive growth. A malignant
tumor mirrors the selective process origi-
nally described by Darwin through a selec-
tive process, rewarding those that grow and
expand unchecked. In the last decade, an at-
tempt to understand how these mutations
lead to cancer was initiated through the de-
velopment of many “micro”-techniques.
These include the use of the microscope,
biochemical and cell biological techniques,
as well as advanced genomic-based tools,
with significant focus in the last decade on
the latter [10].
Since genes regulate the growth of
cells, a natural approach to understanding
cancer is to identify “what genes have gone
awry?” At the time this question was posed,
the technologies to answer these questions
were not well developed. Thus, genomic-
based tools grew out of this need. Southern
blotting, which identifies DNA sequences
using oligonucleotide probe hybridization,
along with the development of the microar-
ray chip, a chip with thousands of embed-
ded probes corresponding to a specific gene,
led to a massive increase in the number of
genes one could simultaneously investigate.
In the last decade, two types of array tech-
nologies played a significant role in our un-
derstanding of how cancer cells differ from
normal cells — one measuring gene expres-
sion and the other gene copy number. Ex-
pression analysis of cancer cells focus on
gene regulation by measuring under/overex-
pressed mRNA in a sample tumor, while the
second focuses on genomic structural
changes via copied and deleted regions of
DNA. Both technologies have their respec-
tive successes and difficulties. For example,
array comparative genomic hybridization
(aCGH) data, or copy number data, explic-
itly informs which regions of the genome
have been altered. However, it is still uncer-
tain which specific genes within the altered
region are aberrantly expressed. Further, ex-
pression analysis can specify the genes that
are under/overexpressed, but do not inform
about the causal molecular mechanisms un-
derlying the gene expression change.
In 2005, building upon the concepts of
Sanger sequencing, rather than microarray
hybridization, sequencing DNA of interest
became the next-generation in genomic dis-
covery technologies [11-15]. Next-genera-
tion sequencing (NGS) is the ability to
sequence DNA samples using a reference li-
brary in a massive parallel capacity, revolu-
tionizing sample resolution and the time
necessary to sequence those samples [12].
While cost initially prohibited this technol-
ogy for widespread use, now NGS is mod-
erately more expensive than microarrays
and in the next 5 months will likely be sim-
ilarly priced [16]. NGS technologies are an
improvement over microarrays for multiple
reasons [17]. First, microarray technology
requires a priori knowledge of the genes of
interest, introducing probe bias, whereas
NGS technologies do not. Second, microar-
ray segments may cross-hybridize to incor-
rect probes introducing noise in the signal,
while NGS technologies rely on sequencing,
which counts single nucleotides. As a con-
sequence of this single base-pair resolution,
NGS technologies can identify point muta-
tions in cancers [18,19]. Finally, nanograms
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of material is needed for NGS, while mi-
croarrays rely on orders of magnitude more,
increasing the reliance on PCR, and thus,
PCR biases have a larger impact on results.
Most microarray technologies now have ap-
propriate analogues to NGS, e.g., expression
arrays to RNA-seq [20] and aCGH to CNV-
seq [21] are among a few. It should be noted,
however, that while NGS will likely replace
array-based technologies, the amount of
samples currently available is still insuffi-
cient for many types of investigations. Thus,
until sufficient NGS samples are collected,
microarrays will still be needed.
Before microarrays or NGS technolo-
gies, researchers focused on single gene hy-
potheses (Figure 1A). While this is a
thorough systematic scientific approach to
cancer biology, it is time consuming since
few genes are investigated
at a time, it is biased, and
the cancer is often simu-
lated with a biological
model. Other steps have
been made to improve this
type of interrogation
through the use of RNA in-
terference that “knocks-
down” mRNA transcripts
[22]. While these scans
allow for many genes to be
interrogated at once, it is
still necessary to define the
set of genes to investigate
and in what type of tissue
and under what conditions.
From one perspective,
it seems that these ap-
proaches could be supple-
mented by suggesting
multiple gene candidates
for validation by starting
with genomic cancer data
(Figure 1B), i.e., let the pat-
tern of expression or copy
number tell us what genes
are interacting. Indeed, cur-
rent technologies inform on
the order of tens-of-thou-
sands of genes, and thus, it
is necessary to amplify the
genes that convey abnormal expression or
copy number resulting from causative mu-
tations. However, even NGS technology has
variability due to random fluctuations in the
cell, and thus, large sample sizes must be
used to investigate these genes. Since col-
lective samples are used, probabilistic meth-
ods must be employed to identify genes of
interest. However, simply identifying genes
of interest does not convey a pathway or
necessarily generate an informative cancer
model. It is the major goal of cancer biology
to map DNA alterations to the causative
function of the genes altered. One way to
understand causation is to look at networks
of interacting genes, i.e., genes whose ex-
pression affects other genes. How to dis-
cover collectively active genes in an
unbiased way, however, is not obvious.
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Figure 1. A shows the typical process of investigating hypo-
thetical gene interactions. A hypothesis is made, experi-
ments are performed, and then a result is obtained. B shows
a typical process in which a microarray informs about hypo-
thetical networks. After many whole genome-wide arrays
have been created, the data is collected together in some al-
gorithmic way (discussed in text) and (a) network(s) of inter-
actions are inferred. Those networks can then be suggested
for biological validation. Networks of gene relations were
generated from a curated protein database with p53 as the
center of the network [43].
Thus, we must also, in a systematic, well-
defined, mathematical way, amplify net-
works of interest using appropriate models.
Luckily, probabilistic network models are
optimized for specifically these tasks. The
derived networks from modeling and ge-
nomic data may then improve understand-
ing of gene interactions in cancer
progression and help link causative muta-
tions to disease.
topicS
The Statistical Tools: Are All Network
Identification Tools Created Equal?
Armed with a massive amount of
probes on a single array or a complete ge-
nomic library from NGS technologies, the
whole genome can now be investigated in
one experiment. While creating a revolution
in cancer, genomic technologies still suffer
from difficulties in data analysis [23-25].
Core issues include noise and testing too
many hypotheses. Since most genes are not
aberrantly expressed in a cell, gene expres-
sion fluctuates about its healthy homeosta-
tic mean. Thus, each gene has a variable
range of expression values that may be any
random value. If we are not careful, we can
mistakenly associate a large deviation from
expression as significant, even though the
expression was just a fluctuation in the can-
cer sample. Biologists attempt to mitigate
this difficulty by increasing the number of
technical replicates, limiting technical er-
rors, as well as increasing biological repli-
cates reducing the impact of “passenger”
genes — genes that are altered, but non-dri-
vers in the cancer.
Despite these efforts, it is still difficult
to distinguish between a significant change
and a normal statistical fluctuation. For ex-
ample, suppose a gene is suspected to be up-
regulated. The expression mean is found
from biological replicates of our cancer and
healthy replicates. These means can be com-
pared using a t-test, which makes the as-
sumption that the t-statistic follows the
t-distribution. If our measurement is signif-
icantly differentially expressed, then the t-
statistic will be in the far tails of the t-distri-
bution, returning a small p-value — a meas-
ure of how extreme an observation is [26].
This problem is further compounded when
we test tens-of-thousands of genes where
there is a greater chance of seeing a large
statistical fluctuation. We need to be even
stricter in what we call a significant expres-
sion change as opposed to a normal statisti-
cal fluctuation. Typically, the p-value is
corrected using, for example, a Bonferonni
correction. This then boils down to filtering
out what gene is important, what gene is not,
and what genes your analysis suggests are
important but really are not. The last of these
three are called “false positives.” These in-
vestigations can be further improved upon
through the use of the false discovery rate
that determines how likely the “positive”
finding is a true positive (a real result)
[27,28].
Often, identification of gene candidates
in cancer samples is insufficient to build a
cancer model, thus sometimes we must at-
tempt to characterize the samples in some
general way based on the genomic alter-
ations measured. One way to accomplish
this task is through cluster analyses, such as
hierarchical clustering, employed by group-
ing genes with similar expression [29],
which often leads to discovery of tumor sub-
types. These types of investigations define
“distances” representing similarity between
gene expression profiles and grouping those
similar ones together. The question here is,
what patterns of gene expression emerge
and are they consistent across samples?
These types of clustering analyses, referred
to as unsupervised learning, often do not in-
form why genes cluster; however, it can
offer inferences into why. Other times, mak-
ing predictions with expression data is used;
supervised learning, for example, utilizes
large sets of data to “train” a model, such as
Random Forest models [30], artificial neural
networks [31], and support vector machines
[32], and then make predictions.
While these analyses help identify in-
teresting genes, aggregate information, and
make predictions, they do not construct net-
works of interacting genes. In this context,
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“interacting” encompasses chemical, syn-
tenic, and indirect regulation of one gene on
another via proteins and other factors such as
non-coding RNAs. Underlying these analy-
ses sits the hope that one could start from
genome-wide experiments and let the aggre-
gated results inform which genes are inter-
acting in a network, not just correlated in a
network. The important distinction here is in-
teracting versus correlations. Correlations
describe only a statistical relationship be-
tween genes, returning a statistic that only in-
forms from sampling the model distribution,
whereas interactions return the model distri-
bution itself (Note: we explicitly define in-
teractions in the next section). Probabilistic
models have thus been designed to build
gene networks using, e.g., Bayesian Net-
works [33], information-theoretic models
[34], deterministic models [35], and sparse-
network methods [36,37]. All of these mod-
els are, in some way, attempting to construct
or help construct a graph, i.e., an abstract
construct that connects vertices (often genes)
with edges (an interaction between those
genes). Each method has its own set of ad-
vantages and disadvantages in terms of ac-
curacy and computational time, and each
method invokes its own set of assumptions
about the nature of the interactions [38]. For
example, deterministic models commonly
referred to as ODEs (ordinary differential
equations) explicitly model the interactions
in terms of relatively simple equations, with-
out noise, but must be fit to a large number of
biological parameters that are often un-
known. Information-theoretic models, while
successful in identifying transcription factors
in cancer [39], cannot handle loops in net-
works and suffer from noise from indirect in-
teractions, which effectively removes
information from the system. Bayesian net-
works while successful are typically compu-
tationally expensive.
A Physics Approach … Going Backward
Physicists traditionally make sense of
natural phenomena by concocting a mathe-
matical model while ensuring experimental
agreement. For example, magnetic forces
may be represented by a mathematical
model constructed between particles and can
generally be written in terms of energies or
interactions between those particles. When
dealing with statistical quantities, those in-
teractions are put into the framework of the
probabilistic model, which defines the prob-
ability of being in a particular state. For ex-
ample, the probability of being in the state
with particle-1 up and particle-2 down, is a
function of the interactions between the two
particles. Recently, physicists have taken an
interest in the inverse-problem, i.e., using
experimental data to reverse-engineer the in-
teractions typically a priori defined. Thus,
back to the geneticist, rather than defining
interactions and examining the resultant sta-
tistical dynamics of altered gene states, we
use the experimental probabilities of being
in a particular expression or copy number
state, for example, gene-1 deleted and gene-
2 amplified, to determine the interactions
between the genes.
As shown by Lezon et al. [40], one can
take this approach and determine the explicit
relationship between gene interactions and
statistically measured quantities, such as a
Pearson correlation. Fortuitously, the proba-
bilistic model parallels the common Spin-
Glass or Ising system physicists have
investigated for decades. With the analogy
that genes are interacting particles, Lezon et
al. successfully showed that the gene inter-
actions are not equal to the expression co-
variance matrix as typically calculated from
expression technologies, but equal to the in-
verse of the covariance matrix. At first
glance, this may be surprising, but these re-
sults exemplify the fact that algorithms that
supplement statistical correlations for gene
interactions are incomplete, otherwise, the
gene interactions would be equal to the co-
variance matrix.
Fortunately, this approach does not suf-
fer from indirect correlations as some of the
other approaches do, delivers the explicit
forces one would typically a priori define
between genes from measured data, may
infer large interactions between genes even
when those genes have low correlations
[41], and it can be vastly improved upon
through the use of dimension reduction al-
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gorithms such as the James-Stein shrinkage
estimator and graphical lasso [36,37]. One
difficulty, however, from this approach is
that directed graphs are not generated (who
causes who is unknown), as modified
Bayesian networks can, such as BANJO
[33]. Ultimately, however, any underlying
network discovered with strong interactions
can only be validated through further exper-
imentation (Figure 1), use of protein-protein
interaction databases, pathway interroga-
tions, and utilizing other genomic based
technologies.
concluSionS
Building gene networks from existing
data is a bottom-up approach attempting to fill
in the gaps and understand gene relations.
While many network algorithms calculate sta-
tistical correlations between genes, they often
do not describe direct causal gene interactions,
which are the explicit biological model we
hope to capture. Improving these computa-
tional methods is likely to be the future of re-
verse-engineering gene networks, and here we
have highlighted some promising approaches
that have borrowed concepts from statistical
physics. In addition, since fundamentally dif-
ferent biochemical genomic technologies rep-
resent different observables, for example,
ChIP-seq [42], combining them with other
measurables will likely lead to dimension re-
duction, improving both gene candidate false
positives as well as reduce noise in gene inter-
action networks. Finally, other non-genomic-
based technologies, such as protein-protein
interaction [43] and pathway [44] databases,
have been curated, which may be used to sup-
plement these investigations as well as validate
discovered networks. It is the hope of cancer
biology that this data may be integrated into a
complete model defining the cancer genome.
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